Cargando…
Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy
SIMPLE SUMMARY: Melanoma is one of the top three causes of brain metastases, which is still a poor prognostic factor of overall survival. Novel systemic therapies have changed the prognosis of patients and the place of local intracranial treatment, surgery and/or radiotherapy in this era remains unc...
Autores principales: | Dalmasso, Céline, Pagès, Cécile, Chaltiel, Léonor, Sibaud, Vincent, Moyal, Elisabeth, Chira, Ciprian, Sol, Jean Christophe, Latorzeff, Igor, Meyer, Nicolas, Modesto, Anouchka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430519/ https://www.ncbi.nlm.nih.gov/pubmed/34503304 http://dx.doi.org/10.3390/cancers13174493 |
Ejemplares similares
-
BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018) -
Helical tomotherapy for post-mastectomy radiation therapy with or without breast implant: a single institution experience
por: Dejean, Romain, et al.
Publicado: (2022) -
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020) -
Management of intracranial melanomas in the era of precision medicine
por: Young, Grace J., et al.
Publicado: (2017) -
Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents
por: Acharya, Sahaja, et al.
Publicado: (2017)